Abstract 173P
Background
Peritoneal metastases (PM) have an extremely poor survival irrespective of the primary cancer type. The reason for poor survival is the lack of therapies and the poor response to systemic treatment. We hypothesize that the peritoneal immune system (PerIS) underlies therapy resistance. The aim of this study was to characterize the PerIS in healthy individuals and patients with PM-colorectal cancer (PM-CRC), to identify novel treatment targets and combat peritoneal carcinomatosis.
Methods
Cellular indexing of transcriptomes and epitopes sequencing (CITE-seq) and single cell RNA-sequencing (scRNA-seq) was used to define the PerIS in peritoneal flushes (PF) from healthy individuals (n=5) and PM-CRC patients (n=13) undergoing elective surgery. The PerIS was compared to peripheral blood mononuclear cells (PBMCs), primary colon tissue and liver tissue. In PM-CRC mouse models (i.p. injection mouse CRC cell line CT26), macrophages were depleted using i.p. anti-CSF1R, with or without anti-PD1 treatment, or vehicle control. Primary outcome was survival and secondary outcomes were the modified peritoneal carcinomatosis index (mPCI) and ascites score.
Results
The healthy PerIS is characterized by immunosuppressive resident C1QA+VSIG4+ macrophages. The PerIS contains significantly more macrophages (mean: 28.0%) compared to colon (mean: 3.2%) and liver (mean: 1.6%). In PM-CRC, these macrophages become even more immunosuppressive with higher gene expression of IL10 and VEGFA and reduced expression of antigen presenting molecules. Moreover, protein levels of cytokines like IL10 (p=0.0006) and VEGFA (p=0.0003) are increased in PF of PM-CRC patients compared to healthy individuals and correlate to the PCI. In PM-CRC, C1Q+SPP1+ infiltrating macrophages were amongst the most abundant immune cells and contributed to immunosuppression. Intriguingly, mice studies demonstrated that anti-CSF1R/anti-PD1 combination therapy effectively reduced mPCI, ascites score and improved survival compared to vehicle control (p=0.0001), anti-CSF1R (p=0.005) and anti-PD1 (p=0.039).
Conclusions
Peritoneal resident macrophages define the peritoneal immunosuppressive niche and are a promising therapeutic target for PM-CRC.
Legal entity responsible for the study
Amsterdam UMC.
Funding
NWO VENI, KWF YIG, TKI grant and Amsterdam UMC PhD scholarship.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
126P - Evaluation of Myeloid Targeting Agents, PY159 and PY314, in Two Dose Expansion Phase 1b Trials in Platinum-Resistant Ovarian Cancer
Presenter: Oladapo Yeku
Session: Poster Display
116TiP - Randomized, open-label, phase II study of botensilimab (BOT) alone and in combination with balstilimab (BAL) versus standard-of-care in patients with refractory metastatic colorectal cancer
Presenter: Eric Van Cutsem
Session: Poster Display
127P - REGN5668 (MUC16xCD28 bispecific antibody) with cemiplimab (anti-PD-1 antibody) in recurrent ovarian cancer: Phase 1 dose-escalation study
Presenter: Ira Winer
Session: Poster Display
128P - A phase I dose escalation and expansion trial of LYT-200, a Galectin-9 antibody +/- tislelizumab
Presenter: Gerald Falchook
Session: Poster Display
129P - Naxitamab efficacy in patients with refractory/relapsed high-risk neuroblastoma and bone metastases as assessed by Curie score
Presenter: Brian Kushner
Session: Poster Display
131P - Safety and clinical efficacy of Roginolisib (IOA-244), the first oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3K_)
Presenter: Anna Di Giacomo
Session: Poster Display
132P - A phase I clinical trial of QLS31905 in advanced solid tumors
Presenter: Yakun Wang
Session: Poster Display
133P - Phase 1/2 study of XTX101, a masked, tumor-activated Fc-enhanced anti-CTLA-4, in patients with advanced solid tumors
Presenter: Diwakar Davar
Session: Poster Display
134P - A Phase 1 Study Exploring the Safety and Tolerability of the Small Molecule PD-L1 Inhibitor INCB099318 in Select Advanced Solid Tumors
Presenter: David Pinato
Session: Poster Display
135P - Isunakinra as Monotherapy and Combined with Nivolumab for Treatment Resistant Advanced Solid Tumours: Exploratory Effect Data, Tolerability, and Pharmacokinetics from a Dose Escalation Trial
Presenter: Carlos Becerra
Session: Poster Display